Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 Gene Polymorphism in Patients with Gastric Ulcer Complicated with Bleeding

Journal of Korean Medical Science

Volumn 18, Issue 1, 2003, Pages 58-64

  Kim, Hong Soo ^a   Hwang, Kyu Yoon ^a   Chung, Il Kwon ^a   Park, Sang Heum ^a   Lee, Moon Ho ^a   Kim, Sun Joo ^a   Hong, Sae Yong ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Fibrinolysis; Hemostasis; Peptic Ulcer; Plasminogen Activator Inhibitor 1; Tissue Plasminogen Activator

Indexed keywords

ENDONUCLEASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTION; DNA POLYMORPHISM; DUODENUM ULCER; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENOTYPE; HEMOSTASIS; HUMAN; INTRON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POLYMERASE CHAIN REACTION; PROMOTER REGION; RECURRENT PEPTIC ULCER; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STOMACH HEMORRHAGE; STOMACH LESION; STOMACH ULCER; ALU SEQUENCE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PEPTIC ULCER BLEEDING; RECURRENT DISEASE;

ADULT; AGED; ALU ELEMENTS; DNA MUTATIONAL ANALYSIS; DUODENAL ULCER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PEPTIC ULCER HEMORRHAGE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECURRENCE; SEQUENCE DELETION; STOMACH ULCER; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0141958654     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.1.58     Document Type: Article

References (36)

1. Valle JD. Peptic ulcer disease and related disorders. In: Braunwald E, et al., ed. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2001: 1649-61.
2. Bogoch A. Bleeding from the alimentary tract. In: Haubrich WS, Schaffner F, eds. Bockus Gastroenterology. Philadelphia: W.B. Saunders, 1995: 61-6.
3. Buffoli F, Graffeo M, Nicosia F, Gentile C, Cesari P, Rolfi F, Paterlini A. Peptic ulcer bleeding: comparison of two hemostatic procedures. Am J Gastroenterol 2001; 96: 89-94.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
5. Lai KC, Hui WM, Wong WM, Wong BC, Hu WH, Ching CK, Lam SK. Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage - a long-term randomized, controlled study. Am J Gastroenterol 2000; 95: 2225-32.
6. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, Chan FK, Ng EK, You JH, Lee CW, Chan AC, Chung SC. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.
7. Sonnenberg A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94: 950-4.
8. Lau JY, Sung JJ, Lam YH, Chan AC, Ng EK, Lee DW, Chan FK, Suen RC, Chung SC. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340: 751-6.
9. Chung IK, Ham JS, Kim HS, Park SH, Lee MH, Kim SJ. Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers. Gastrointest Endosc 1999; 49: 13-8.
10. Swain CP, Storey DW, Bown SG, Heath J, Mills TN, Salmon PR, Northfield TC, Kirkham JS, O'Sullivan JP. Nature of the bleeding vessel in recurrently bleeding ulcers. Gastroenterology 1986; 90: 595-608.
11. Garcia Rodriguez LA, Jick H. The risk of upper gastrointestinal bleeding and/or perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
12. Kurata J, Abbey D. The effect of chronic aspirin use on duodenal and gastric ulcer. J Clin Gastroenterol 1990; 12: 260-6.
13. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-9.
14. Kovas TOG, Jensen DM. Complication of peptic ulcer disease. In: DiMarino AJ, Benjamin SB, eds. Gastrointestinal disease: an endoscopic approach. Massachusetts: Blackwell Science, 1997; 475-94.
15. Herszenyi L, Plebani M, Carraro P, De Paoli M, Cardin R, Di Mario F, Kusstatscher S, Naccarato R, Farinati F. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 1997; 92: 843-7.
16. Wodzinski MA, Bardhan KD, Reilly JT, Cooper P, Preston FE. Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease. Gut 1993; 34: 1310-4.
17. Stenberg B, Bylock A, Risberg B. Local fibrinolytic activity and its structural basis in experimental gastric ulcers. Eur J Clin Invest 1983; 13: 297-300.
18. Stenberg B, Karlsson L, Alpsten M, Risberg B. Reduction of gastric haemorrhage by fibrinolysis inhibition-an experimental study in rats. Thromb Haemost 1983; 49: 106-8.
19. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
20. Hong SY, Yang DH, Shin HK. Effect of nerve block on t-PA release by venous occlusion. Fibrinolysis 1992; 6: 131-5.
21. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
22. Zöller B, Garcia de Frutos P, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost 1998; 79: 802-7.
23. Stegnar M, Uhrin P, Petemel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975-9.
24. Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, Espana F, Cano A, Segui R, Aznar J. Plasminogen activator inhibitor-1 promoter 4G/ 5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999; 81: 516-21.
25. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele .sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
26. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk of this disease. Thromb Haemost 1999; 82: 1121-6.
27. Ioviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-30.
28. Iocoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
29. Makalewski W, Mitchell GA, Labuda D. Alu sequence in the coding regions of mRNA: a source of protein variability. Trends Genet 1994; 10: 188-93.
30. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis. Thromb Haemost 1995; 74: 1202.
31. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction: the Rotterdam study. Circulation 1997; 95: 2623-7.
32. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verbürg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonstemidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS studv: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
33. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-stemidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis 2000; 32: 138-51.
34. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615-25.
35. Piotrowski J, Czajkowski A, Yotsumoto F, Slomiany A, Slomiany BL. Sulglycotide effect of the proteolytic and lipolytic activities of Helicobacter pylori toward gastric mucus. Am J Gastroenterol 1994; 89: 232-6.
36. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.